Home > PORTAL > About Us > Presentation >
Learn how SPIN got started
SPIN – Skin Inflammation & Psoriasis International Network was initiated in 2004 as PIN – Psoriasis International Network by the FRT - Fondation René Touraine, a non-profit and a non-governmental organisation dedicated to support therapeutic progress in dermatology by fostering international collaborations.
After several European meetings on psoriasis held in Italy every 2 or 3 years, the FRT and Prof. Louis Dubertret organised the European Congress on Psoriasis - PSO 2004 in Paris, which acquired a great international dimension, with over 600 participants from 40 different countries. Following the PSO 2004 Congress, many participants showed great interest in developing networking activities in the field of psoriasis.
The founding meeting of the former PIN was held in Paris (Nov 18, 2005) between 20 countries willing to develop national psoriasis groups and willing to connect these groups into an international network. 11 countries were able to send a representative and 9 additional countries expressed a strong interest but were unable to come. The President of EUROPSO, the European federation of psoriasis associations, participated as well in the founding meeting.
This founding meeting formalised the international collaborations in the field of psoriasis started with the PSO 2004 Congress, creating thus the Psoriasis International Network. To develop this international network, it was proposed to:
• set up a website: www.psoriasis-international.org (now www.spindermatology.org!)
• organise every 3 years an International Congress on Psoriasis in Paris
• publish regular newsletters and "Focus On”
In 2011, a Scientific Committee was created to steer the scientific development of the network by proposing international collaborative projects, contributing to continuing medical training in psoriasis and supporting the development of national and regional psoriasis networks.
The network has grown ever since, gathering around 4700 healthcare professionals involved in the management of psoriasis from some 100 countries, 330 dermatology centres as well as 43 patient organisations. Since 2004, PIN has successfully:
• organised 5 international congresses on psoriasis and educational symposia during other dermatology meetings
• built a worldwide directory listing psoriasis medical resources for patients
• provided organisational support to the development of dedicated outpatient consultations at the local level
• fostered the development of national and regional networks on psoriasis
• carried out international studies on the current practice of the use of methotrexate and phototherapy in the treatment of psoriasis
• initiated a worldwide survey on the use of therapeutic patient education in psoriasis with the aim of developing a toolbox
• collaborated with the EADV Psoriasis Task Force since 2005.
In 2016, it was decided by the FRT Board of Directors to broaden the scope of the PIN to include other major chronic inflammatory skin diseases. This would allow to benefit from the benchmark of PIN’s actions and achievements in psoriasis and put it to the service of other diseases. With this change, we hope to transfer the know-how acquired on psoriasis (highest standard in issues such as quality of life, high burden and co-morbidities) and build on the collaborations made possible via the PIN network and expand them to other major chronic skin inflammatory diseases.
Following this decision, the former PIN Scientific Committee has decided to change the name of the network to SPIN – Skin Inflammation & Psoriasis International Network. On an operational level, the Committee decided to broaden the network’s scope progressively, one chronic inflammatory skin disease at a time. Starting in 2017, the new SPIN will cover psoriasis and expand its activities to atopic dermatitis.
Directory of Psoriasis
Medical Resources
SPIN Presentation
Recent news
-
2018/07/16 Focus on...
-
2018/07/09 Focus on...
-
2018/04/18
News from the web office
-
2016/10/29
-
2016/05/26
-
2016/02/20
Events
-
2018/02/21
-
2017/06/21
News from medical groups
-
2018/04/18
-
2017/06/21
News from patients associations
-
2017/02/08
-
2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Genomic alterations driving psoriasis pathogenesis.
Singh S et al.
Genomic alterations driving psoriasis pathogenesis.
Gene.
2019 Jan 30, 683:61-71.
Psoriasis is an immune mediated inflammatory skin disease with complex etiology involving interplay between environmental and genetic risk factors as disease initiating event. Enhanced understanding on genetic risk factors, differentially expressed genes, deregulated proteins and pathway-targeted therapeutics have established multiple axis of psoriasis pathogenesis. So far, loci in 424 genes are reported to be associated with psoriasis alongside copy number variations and epigenetic (...)
see on pubmed
Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review.
J. Cell. Physiol..
2019 Feb , 234, (2):1165-1178.
Curcumin, a natural polyphenolic and yellow pigment obtained from the spice turmeric, has strong antioxidative, anti-inflammatory, and antibacterial properties. Due to these properties, curcumin has been used as a remedy for the prevention and treatment of skin aging and disorders such as psoriasis, infection, acne, skin inflammation, and skin cancer. Curcumin has protective effects against skin damage caused by chronic ultraviolet B radiation. One of the challenges in maximizing the (...)
see on pubmed
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris.
Psychol Health Med.
2019 Mar , 24, (3):269-280.
Previous studies have reported a higher incidence of depression and anxiety in psoriasis patients compared to the general population, which has important implications for assessment and treatment. In this study, we determined the frequency of depression and anxiety in Chinese patients with psoriasis and its relationship with disease severity and other demographic variables. The study included 208 Chinese patients with psoriasis vulgaris. The Patient Health Questionnaire (PHQ-9) and (...)
see on pubmed
on Atopic Dermatitis
Atopic Dermatitis: New Developments.
Kusari A et al.
Atopic Dermatitis: New Developments.
Dermatol Clin.
2019 Jan , 37, (1):11-20.
Herein we review recent developments in our understanding and treatment of atopic dermatitis. Key insights from the recent literature are summarized, from findings on the pathogenesis of this multifactorial disease to a new and more nuanced understanding of its natural history. Therapeutic advances and new data on comorbidities are also discussed.
see on pubmed
Comorbidities in Dermatology: What's Real and What's Not.
Qureshi A et al.
Comorbidities in Dermatology: What's Real and What's Not.
Dermatol Clin.
2019 Jan , 37, (1):65-71.
Comorbidities affecting dermatologic patients are of significant importance to providers and highly relevant for appropriate patient counseling, screening practices, prevention, and treatment. This article seeks to highlight several of the newest findings in the literature regarding comorbidities associated with dermatologic diseases including atopic dermatitis, hidradenitis suppurativa, alopecia areata, chronic urticaria, and the pemphigus family of immunobullous diseases. Further (...)
see on pubmed
Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March.
Allergy Asthma Immunol Res.
2019 Jan , 11, (1):4-15.
The Atopic march denotes the progression from atopic dermatitis (AD) to the development of other allergic disorders such as immunoglobulin (Ig) E-mediated food allergy, allergic rhinitis and asthma in later childhood. There is increasing evidence from prospective birth cohort studies that early-onset AD is a risk factor for other allergic diseases or is found in strong association with them. Animal studies now provide mechanistic insights into the pathways that may be responsible for (...)
see on pubmed